[HTML][HTML] Cardiovascular disease models: a game changing paradigm in drug discovery and screening

H Savoji, MH Mohammadi, N Rafatian, MK Toroghi… - Biomaterials, 2019 - Elsevier
Cardiovascular disease is the leading cause of death worldwide. Although investment in
drug discovery and development has been sky-rocketing, the number of approved drugs has …

Translation of human-induced pluripotent stem cells: from clinical trial in a dish to precision medicine

N Sayed, C Liu, JC Wu - Journal of the American College of Cardiology, 2016 - jacc.org
The prospect of changing the plasticity of terminally differentiated cells toward pluripotency
has completely altered the outlook for biomedical research. Human-induced pluripotent …

High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells

A Sharma, PW Burridge, WL McKeithan… - Science translational …, 2017 - science.org
Tyrosine kinase inhibitors (TKIs), despite their efficacy as anticancer therapeutics, are
associated with cardiovascular side effects ranging from induced arrhythmias to heart …

[HTML][HTML] Cardiomyocytes from human pluripotent stem cells: from laboratory curiosity to industrial biomedical platform

C Denning, V Borgdorff, J Crutchley, KSA Firth… - … et Biophysica Acta (BBA …, 2016 - Elsevier
Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise
biomedicine. Global burden of heart failure will soon reach USD $90 bn, while unexpected …

Patient and disease–specific induced pluripotent stem cells for discovery of personalized cardiovascular drugs and therapeutics

DT Paik, M Chandy, JC Wu, EH Ohlstein - Pharmacological reviews, 2020 - Elsevier
Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for
regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production …

Dilated cardiomyopathy in the era of precision medicine: latest concepts and developments

N Orphanou, E Papatheodorou, A Anastasakis - Heart failure reviews, 2022 - Springer
Dilated cardiomyopathy (DCM) is an umbrella term entailing a wide variety of genetic and
non-genetic etiologies, leading to left ventricular systolic dysfunction and dilatation, not …

Induced pluripotent stem cells for cardiovascular disease modeling and precision medicine: a scientific statement from the American Heart Association

K Musunuru, F Sheikh, RM Gupta… - Circulation: Genomic …, 2018 - Am Heart Assoc
Induced pluripotent stem cells (iPSCs) offer an unprece-dented opportunity to study human
physiology and disease at the cellular level. They also have the potential to be leveraged in …

Miniaturized iPS-cell-derived cardiac muscles for physiologically relevant drug response analyses

N Huebsch, P Loskill, N Deveshwar, CI Spencer… - Scientific reports, 2016 - nature.com
Tissue engineering approaches have the potential to increase the physiologic relevance of
human iPS-derived cells, such as cardiomyocytes (iPS-CM). However, forming Engineered …

Patient-specific and genome-edited induced pluripotent stem cell–derived cardiomyocytes elucidate single-cell phenotype of Brugada syndrome

P Liang, K Sallam, H Wu, Y Li, I Itzhaki, P Garg… - Journal of the American …, 2016 - jacc.org
Abstract Background: Brugada syndrome (BrS), a disorder associated with characteristic
electrocardiogram precordial ST-segment elevation, predisposes afflicted patients to …

Use of human induced pluripotent stem cell–derived cardiomyocytes to assess drug cardiotoxicity

A Sharma, WL McKeithan, R Serrano, T Kitani… - Nature protocols, 2018 - nature.com
Cardiotoxicity has historically been a major cause of drug removal from the pharmaceutical
market. Several chemotherapeutic compounds have been noted for their propensities to …